A study of targeting therapy for MDSC in oral cancer.
| Project/Area Number |
26861576
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Pathobiological dentistry/Dental radiology
|
|---|
| Research Institution | Yokohama City University |
|---|
Principal Investigator |
SATO Yuki 横浜市立大学, 医学(系)研究科(研究院), 客員研究員 (60573277)
|
|---|
| Project Period (FY) |
2014-04-01 – 2016-03-31
|
| Project Status |
Completed (Fiscal Year 2015)
|
| Budget Amount *help |
¥3,770,000 (Direct Cost: ¥2,900,000、Indirect Cost: ¥870,000)
Fiscal Year 2015: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2014: ¥2,470,000 (Direct Cost: ¥1,900,000、Indirect Cost: ¥570,000)
|
|---|
| Keywords | 口腔癌 / 分子標的薬 / MDSC |
|---|
| Outline of Final Research Achievements |
At first, we used 4T1 breast cancer mouse model, because mouse oral squamous cell cancer cells, SCC-7 was not able to established the tumor in mice. We observed expression of IL-13Ra2 in MDSCs isolated from 4T1 tumor moice. MDSCs, CD11b(+)Gr-1(+) sorted from mice splenocytes were highly expressing IL13Ra2 compared to CD11b(-)Gr-1(-) cells by FACS analysis. Then, we found that IL13-PE, targeting for IL-13Ra2, could directly kill MDSCs. It was suggested that targeting therapy for IL13Ra2 may be useful to eliminate not only tumor, but also MDSCs.
|
Report
(3 results)
Research Products
(1 results)
